NRD
RARE icon

Nebula Research & Development’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nebula Research & Development’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,876
Closed -$373K – 1114
2024
Q4 		$373K Buy
8,876
+4,655
+110% +$231K 0.04% 652
2024
Q3 		$234K Buy
+4,221
New +$215K 0.03% 790
2023
Q2 		– Sell
-8,050
Closed -$323K – 429
2023
Q1 		$323K Buy
+8,050
New +$345K 0.57% 5

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Nebula Research & Development's RARE Position: Q1 2025 in Review

Nebula Research & Development sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 8,876 shares — an estimated $373K sold.

Nebula Research & Development first reported a position in RARE in Q1 2023 and held it in 3 quarters. The position peaked at $373K in Q4 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

  • Nebula Research & Development reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Nebula Research & Development sold 8,876 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $373K.
  • Nebula Research & Development first reported a position in Ultragenyx Pharmaceutical in Q1 2023 and held it in 3 quarters.
  • Nebula Research & Development's Ultragenyx Pharmaceutical position peaked at $373K in Q4 2024.
  • 299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on Nebula Research & Development's 13F filing for Q1 2025, filed 15 May 2025.